Post-earnings recap
Reported
Wed, Nov 3, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report shows that 10X Genomics managed to beat expectations on EPS, which contributed to a positive stock reaction, with shares rising 1.33%. However, the lack of revenue data and guidance leaves some uncertainty about future performance. Investors may be encouraged by the EPS surprise but will likely look for more detailed financial metrics in future reports.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.15 | N/A | +18.48% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a cautiously optimistic outlook, emphasizing their commitment to innovation and market expansion. They acknowledged challenges but remained focused on long-term goals.
Management highlighted ongoing advancements in their technology.
They expressed confidence in their long-term growth strategy.
There was a focus on expanding market opportunities despite current challenges.